Brief: Revelation Biosciences Doses First Patient In Prime Phase 1B Clinical Study Of Gemini In CKD Patients
26/02/2025 12:51
Feb 26 (Reuters) - Revelation Biosciences Inc REVB.O: REVELATION BIOSCIENCES DOSES FIRST PATIENT IN PRIME PHASE 1B CLINICAL STUDY OF GEMINI IN CKD PATIENTS REVELATION BIOSCIENCES INC - TOP-LINE DATA EXPECTED BY MID-YEAR Source text: ID:nBw4fk9lga Further company coverage: REVB.O ((Reuters.Briefs@thomsonreuters.com;))